The cardio-oncologic burden of breast cancer: molecular mechanisms and importance of preclinical models DOI Creative Commons
Jürgen Bräuer,

M. Tumani,

Norbert Frey

et al.

Basic Research in Cardiology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 2, 2024

Abstract Breast cancer, the most prevalent cancer affecting women worldwide, poses a significant cardio-oncological burden. Despite advancements in novel therapeutic strategies, anthracyclines, HER2 antagonists, and radiation remain cornerstones of oncological treatment. However, each carries risk cardiotoxicity, though molecular mechanisms underlying these adverse effects differ. Common include DNA damage response, increased reactive oxygen species, mitochondrial dysfunction, which are key areas ongoing research for potential cardioprotective strategies. Since also essential effective tumor cytotoxicity, we explore tumor-specific effects, particularly hereditary breast linked to BRCA1 BRCA2 mutations. These genetic variants impair repair mechanisms, increase tumorigenesis possibly cardiotoxicity from treatments such as anthracyclines antagonists. Novel therapies, including immune checkpoint inhibitors, used clinic triple-negative improve outcomes patients. This review discusses BRCA dysfunction associated pathological pathways. It gives an overview preclinical models genetically engineered mouse models, syngeneic murine humanized various vitro ex vivo systems study cardiovascular side therapies. Understanding mechanism developing strategies improving treatment reducing long-term risks

Language: Английский

Immuno-related cardio-vascular adverse events associated with immuno-oncological treatments: an under-estimated threat for cancer patients DOI Creative Commons
Giuseppe Panuccio, Pierpaolo Correale, Maria D’Apolito

et al.

Basic Research in Cardiology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 3, 2024

Abstract Immunotherapy represents an emergent and heterogeneous group of anticancer treatments harnessing the human immune-surveillance system, including immune-checkpoint inhibitor monoclonal antibodies (mAbs), Chimeric Antigen Receptor T Cells (CAR-T) therapy, cancer vaccines lymphocyte activation gene-3 (LAG-3) therapy. While remarkably effective against several malignancies, these therapies, often in combination with other treatments, have showed unforeseen toxicity, cardiovascular complications. The occurrence immuno-mediated adverse (irAEs) events has been progressively reported last 10 years. These irAEs present extended range severity, from self-limiting to life-threatening conditions. Although recent guidelines CardioOncology provided important evidence managing they encompass general approaches. However, a specific focus is required due particular etiology, unique risk factors, associated side effects immunotherapy. This review aims deepen understanding prevalence nature issues patients undergoing immunotherapy, offering insights into strategies for stratification management.

Language: Английский

Citations

7
Cardio-oncology: chances and challenges DOI
Adriana E. Viñas-Mendieta,

A. Gallardo-Grajeda,

Teresa López‐Fernández

et al.

Basic Research in Cardiology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 30, 2024

Language: Английский

Citations

6
Baicalin reduced vandetanib induced myocardial injury by regulating redox balance and NLRP3 inflammasome pathway DOI
Fen Wang, Jianwei Li, Zhixuan Zhang

et al.

Tissue and Cell, Journal Year: 2025, Volume and Issue: 94, P. 102795 - 102795

Published: Feb. 16, 2025

Language: Английский

Citations

0
Autoimmune-related adverse events induced by immune checkpoint inhibitors DOI
Yini Sun, Ziyang Zhang, Jia Ke

et al.

Current Opinion in Immunology, Journal Year: 2025, Volume and Issue: 94, P. 102556 - 102556

Published: April 11, 2025

Language: Английский

Citations

0
The cardio-oncologic burden of breast cancer: molecular mechanisms and importance of preclinical models DOI Creative Commons
Jürgen Bräuer,

M. Tumani,

Norbert Frey

et al.

Basic Research in Cardiology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 2, 2024

Abstract Breast cancer, the most prevalent cancer affecting women worldwide, poses a significant cardio-oncological burden. Despite advancements in novel therapeutic strategies, anthracyclines, HER2 antagonists, and radiation remain cornerstones of oncological treatment. However, each carries risk cardiotoxicity, though molecular mechanisms underlying these adverse effects differ. Common include DNA damage response, increased reactive oxygen species, mitochondrial dysfunction, which are key areas ongoing research for potential cardioprotective strategies. Since also essential effective tumor cytotoxicity, we explore tumor-specific effects, particularly hereditary breast linked to BRCA1 BRCA2 mutations. These genetic variants impair repair mechanisms, increase tumorigenesis possibly cardiotoxicity from treatments such as anthracyclines antagonists. Novel therapies, including immune checkpoint inhibitors, used clinic triple-negative improve outcomes patients. This review discusses BRCA dysfunction associated pathological pathways. It gives an overview preclinical models genetically engineered mouse models, syngeneic murine humanized various vitro ex vivo systems study cardiovascular side therapies. Understanding mechanism developing strategies improving treatment reducing long-term risks

Language: Английский

Citations

1